CHOOSE BY ALPHABET

A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W | Y | Z

Enter our
BLOG

Follow HFN

News

Dec 11, 2018

HFN Represents Entera Bio in $270m Amgen Licensing Deal

HFN Partners Yair Geva, Tomer FarkashDan Sharot, and Ofer Granot, together with Associate Michal Shirin,  represented Israeli biopharmaceutical company Entera Bio in a $270 million research collaboration and licensing agreement deal with California-based, biopharmaceutical company Amgen Inc. 

Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that  Amgen  has selected.  Amgen also has an option to select up to two additional programs to include in the collaboration.

Click here for further reading.

Back